Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled SNSP113 in Healthy Subjects and Cystic Fibrosis
NCT03309358Phase 1Terminated
- Sponsor
- Synspira Therapeutics
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing Inhaled SNSP113 with Inhaled Placebo (2 arms). Primary endpoints: Incidence of adverse events at 8 days, Spirometry at 8 days and 1 more. Started Sep 2017; status: terminated.
02
Drugs
poly (acetyl, arginyl) glucosamine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03309358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309358.